NewAmsterdam Pharma presented a comprehensive suite of new preclinical and clinical data at the European Atherosclerosis Society (EAS) Congress. Detailed efficacy and safety data from the BROOKLYN trial showed obicetrapib reduced LDL-C by 36.3% at day 84 and 41.5% at day 365 in HeFH patients, alongside reductions in ApoB, non-HDL-C, and Lp(a), and increases in HDL-C, with a safety profile comparable to placebo.
New data highlighted obicetrapib's effect on lipophilic antioxidants, demonstrating significant increases in concentrations of lutein, zeaxanthin, α-tocopherol, ApoE, and S1P in HDL subfractions. This suggests a potential role in diseases associated with low HDL and antioxidant levels, such as age-related macular degeneration and neurodegenerative disorders.
Preclinical studies presented showed obicetrapib reduced atherosclerosis development, primarily by decreasing non-HDL-C levels, and exhibited synergy with ezetimibe in preventing plaque formation in APOE*3-Leiden.CETP mice. Further preclinical data indicated obicetrapib increased VLDL clearance and reverse cholesterol transport without affecting VLDL production.
A pooled analysis of the BROADWAY and BROOKLYN trials revealed that obicetrapib reduced HbA1c and showed a consistent trend toward a lower risk of new-onset diabetes in patients without diabetes at baseline. Additionally, clinical data demonstrated obicetrapib's efficacy when administered with moderate-intensity statins, reducing atherogenic lipoproteins and increasing HDL-C while maintaining a good tolerability profile.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.